
LeMaitre Vascular (LMAT) Stock Forecast & Price Target
LeMaitre Vascular (LMAT) Analyst Ratings
Bulls say
LeMaitre Vascular Inc. demonstrated a strong financial performance in the second quarter of 2025, with a gross margin increase of 110 basis points to 70.0%, attributed to higher average selling prices (ASPs) and improved manufacturing efficiencies. The company reported a 15% increase in revenue on both an as-reported and organic basis, supported by substantial year-over-year growth across all geographic segments: a 12% increase in the Americas, a 23% increase in EMEA, and a 12% increase in APAC sales. Additionally, the positive outlook is reinforced by an upward revision of the calendar year 2025 revenue estimate to $252.6 million, reflecting a robust performance in Q2 and enhancements in the salesforce's efficiency.
Bears say
LeMaitre Vascular Inc. faces a negative outlook due to a revision in its sales force target for FY/25, decreasing from 170 to 165 representatives, indicating potential challenges in future sales growth. Furthermore, the company's inability to maintain or increase selling prices may lead to reduced sales growth and negatively impact operating results. Lastly, the significant decline of approximately 17% year-over-year in research and development expenses to $3.5 million raises concerns about the firm's commitment to innovation and long-term growth prospects.
This aggregate rating is based on analysts' research of LeMaitre Vascular and is not a guaranteed prediction by Public.com or investment advice.
LeMaitre Vascular (LMAT) Analyst Forecast & Price Prediction
Start investing in LeMaitre Vascular (LMAT)
Order type
Buy in
Order amount
Est. shares
0 shares